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Aim: To evaluate the beneﬁts of initiating insulin at an earlier versus later treatment stage, and regimens with/without sulfonylurea (SU).
Methods: Pooled analysis of 11 prospective randomized clinical trials, including 2171 adults with uncontrolled type 2 diabetes initiating
insulin glargine following a speciﬁc titration algorithm. Clinical outcomes were glycated haemoglobin A1c (HbA1c) reduction, per cent achieving
HbA1c ≤ 7.0%, weight gain and hypoglycaemic events. Statistical analysis compared outcomes 24 weeks after basal insulin initiation in
patients previously uncontrolled on 0/1 oral antidiabetic drug (OAD) versus 2 OADs, and in patients taking metformin (MET) or SU alone or in
combination at baseline. A meta-analysis was also conducted.
Results: For the pooled analysis, patients on 0/1 OAD and those on MET monotherapy at baseline had the largest 24-week reductions in
HbA1c following the addition of insulin glargine (∼0.44 U/kg). Of patients failing MET/SU monotherapy and MET + SU in combination, 68.1,
50.4 and 56.4% achieved HbA1c ≤ 7.0%, respectively (p = 0.0006). Weight gain was lowest when basal insulin was added to MET. Patients
on 0/1 OAD at baseline had signiﬁcantly less symptomatic hypoglycaemia when basal insulin was added than those on 2 OADs (p = 0.0007).
Despite higher insulin doses, those taking MET alone had less hypoglycaemia than those taking SU or MET + SU. Results were conﬁrmed in the
meta-analysis.
Conclusion: Adding insulin glargine to MET monotherapy early in treatment may provide efﬁcacy/safety beneﬁts over regimens including
SU. This may reﬂect treatment earlier in the disease and supports the inclusion of insulin as a second step in the American Diabetes
Association/European Association for the Study of Diabetes treatment algorithm.
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Introduction
In 2009, the American Diabetes Association and the Euro-
pean Association for the Study of Diabetes (ADA/EASD)
issued a consensus statement on the initiation and adjust-
ment of therapy for type 2 diabetes [1]. This statement
highlighted the critical importance of promptly achieving gly-
caemic control [i.e. glycated haemoglobin A1c (HbA1c) level
of <7.0%], given the evidence that diagnosis and interven-
tion early in the course of the disease process leads to lower
HbA1c levels over time and reduces the risk of diabetes-related
long-term complications [1,2]. With this goal in mind, the
consensus algorithm adopted a tiered approach in which
tier 1 interventions—well-validated core therapies—were
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deemed to ‘represent the best established and most effective
and cost-effective therapeutic strategy for achieving the tar-
get glycaemic goals’ [1]. These tier 1 interventions included
lifestyle modiﬁcation and metformin (MET) concomitantly
initiated at step 1, the addition of either basal insulin or sul-
fonylurea(SU) therapy to MET at step 2 (if glycaemicgoals are
not achieved with MET alone), and the addition or intensiﬁca-
tion of insulin therapy as needed to attain glycaemic control at
step 3 [1].Inroutineclinicalpractice,however,insulintherapy
ismoreofteninitiatedaftertwoormoreoralantidiabeticdrugs
(OADs) have proven inadequate to achieve or maintain gly-
caemic control. The reasons for delaying insulin initiation are
varied, but may include patient and physician perceptions that
insulin therapyregimens aretoocomplex,concernsabout self-
administering injections, or fears regarding side effects such as
hypoglycaemia and weight gain [3,4].
For these reasons, we sought to use the extensive clinical
trial database of insulin glargine to assess the observed clini-
cal outcomes of earlier versus later basal insulin initiation on
glycaemic control and safety after 24 weeks of treatment. We
conducted a pooled analysis of randomized, controlled trialsDIABETES, OBESITY AND METABOLISM original article
to compare clinical outcomes after initiating insulin glargine
in patients with uncontrolled type 2 diabetes on 0 or 1 OAD
versus 2 OADs at baseline and to determine if there are any
differences between regimens containing MET alone, SU alone
or MET + SU together. We also performed a meta-analysis to
evaluate the robustness of the pooled analysis and to control
for differences in sample size.
Methods
Study and Patient Selection Criteria for Pooled Analysis
In total, 63 randomized controlled trials evaluating insulin
glargine in patients with type 2 diabetes have been conducted
by sanoﬁ-aventis or predecessor companies of sanoﬁ-aventis.
These studies were performed between 1997 and 2007, and
individual patient data were available for inclusion in pooled
analyses. Studies were deemed eligible for pooling if they met
the following criteria:
• were phase 3 or later, prospective, randomized, controlled
trials of ≥24 weeks’ duration;
• enrolled adult patients with type 2 diabetes with inadequate
glycaemic control;
• basal insulin was given once daily, with no concomitant
prandial or bolus insulin administration;
• insulin glargine was initiated at 10 U/days and was
administered according to predeﬁned titration algorithms
with frequent insulin dose adjustment (from every 1 to
3 days,toeveryweek)toachievefastingplasmaglucoselevels
<100 mg/dl (<5.5 mmol/l); and
• studies were conducted according to Good Clinical Practice
and in accordance with the Declaration of Helsinki.
Twelve studies met these eligibility criteria; however, one
study discontinued thiazolidinediones abruptly at baseline
and was not included in this analysis. Therefore, data from
11 studies were used in the pooled analysis (Table 1) [5–14]
(Data on ﬁle, HOE-901-4021). In all studies, baseline OADs
were to remain stable throughout the treatment period. Only
data from patients in the insulin glargine arm of each of the 11
trials were examined for inclusion in this analysis (n = 2171).
For patients in studies having treatment durations longer than
24 weeks, only data from the ﬁrst 24 weeks were used.
Clinical Outcomes
Studyendpointsforthisanalysisincludedweek 24HbA1clevel
and change from baseline, the percentage of patients reaching
at a r g e tH b A 1 cl e v e lo f≤7.0%, change in body weight from
baseline, insulin dose at endpoint and symptomatic and severe
hypoglycaemic incidence and event rates during the treatment
period.
Statistical Analysis
HbA1clevelandchangefrombaselinetoweek24wereanalysed
continuously with an analysis of covariance (ancova)m o d e l
with baseline OAD use (OADs used up to the day before
randomization) and study as factors and baseline HbA1c
as a covariate. Week 24 HbA1c was dichotomized to ≤7.0
and >7.0%. The general association between the success of
reaching target HbA1c and the use of OADs at baseline was
assessed by a Cochran–Mantel–Haenszel (CMH) statistical
test by controlling studies. Change from baseline to week 24 in
body weight was analysed by an ancova model with baseline
OAD classes and study as factors and baseline body weight as
a covariate. The number and proportion of patients who had
hypoglycaemia were analysed by the CMH test. Event rates per
subject year were calculated and analysed continuously with
an analysis of variance model, with study and baseline OAD
classes as factors. Symptomatic hypoglycaemia was deﬁned
as all reported hypoglycaemia events with symptoms. Severe
symptomatic hypoglycaemia was deﬁned as all symptomatic
hypoglycaemia requiring assistance with a blood glucose level
of<36mg/dl(<2mmol/l;ifavailable),andapromptresponse
to treatment with oral carbohydrates, intravenous glucose or
glucagon.
Table 1. Clinical trials included in pooled and meta-analysis.
Study reference (study no.) Treatment/ comparator
Treatment
duration (weeks) N (total) n (insulin glargine)
Gerstein et al.∗ [5] (3502) Insulin glargine/OADs 26 405 197
Riddle et al.∗ [6] (4002) Insulin glargine/NPH insulin 24 756 355
Standl et al. [7] (4009) Insulin glargine (AM)/insulin glargine (PM) 24 624 590
Rosenstock et al. [8] (4014) Insulin glargine/rosiglitazone 24 219 104
Meneghini et al. [14] (4020) Insulin glargine/pioglitazone 24/48 353 159
Data on ﬁle, HOE-901-4021 (4021) Insulin glargine/insulin lispro 75/25 24 212 112
Janka et al. [9] (4027) Insulin glargine/NPH insulin 70/30 28 371 175
Bretzel et al.∗ [10] (4040) Insulin glargine/insulin lispro 44 415 198
Yki-Jarvinen et al.∗ [11] (4041) Insulin glargine (group education)/insulin glargine
(individual education)
24 121 119
Blickle et al. [12] (4042) Insulin glargine/hygienic and dietary measures 40 215 101
Yki-Jarvinen et al.∗ [13] (6001) Insulin glargine/NPH insulin 36 110 61
Pooled analysis Insulin glargine 24 — 2171
Meta-analysis Insulin glargine 24 — 930
OAD, oral antidiabetic drug.
∗Studies included in the meta-analysis.
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Meta-analysis Study Selection
We conducted a meta-analysis of studies to further explore the
effects of the addition of basal insulin in participants uncon-
trolled on 0/1 versus 2 OADs and any signiﬁcant differences
when added to MET versus MET + SU or SU only.This analy-
sisfunctionedasasensitivityanalysistoassesstherobustnessof
the pooled analysis while controlling for effects such as sample
size. Figure 1 shows the ﬂow of information for the systematic
review. To identify any additional studies similar to the trials
in the pooled analysis for possible inclusion, we performed a
thorough literature search of PubMed using the search terms
‘insulin glargine’ and ‘type 2 diabetes’ for articles published
before 18 June 2010. Titles were reviewed to identify random-
ized, controlled clinical trials in patients with type 2 diabetes
treated with basal insulin glargine alone (no prandial insulin).
StudiesmusthavebeenavailableinEnglish,andhaveglycaemic
outcomes.Abstractsandfulltextarticleswerereviewedtodeter-
mineifthe studyincluded patientswhowere insulin-naiveand
inadequately controlled on OADs prior to randomization to
basal insulin therapy, if they reported the number of patients
achieving glycaemic control (HbA1c ≤ 7.0%) at ≥24 weeks
with0/1versus2OADs,METversusMET + SUandSUversus
MET + SU as outcomes, and used insulin titration algorithms.
Of 977 articles initially identiﬁed for review, only 5 met the
strict criteria for inclusion in this meta-analysis [5–14]. All
ﬁve of these articles were included in the 11 studies that were
includedinthepooledanalysis(Table 1).Theothersixstudies,
included in the pooled analysis, did not qualify because all
patients were taking 1 OAD only or ≥2 OADs only at baseline.
Meta-analysis Statistical Methodology
For this meta-analysis, the effect sizes were calculated as:
(1) log odds ratio (OR) of glycaemic control (week 24 HbA1c
≤7.0%) for 0/1 OAD versus 2 OADs, as well as for MET
versus MET + SU, SU versus MET + SU and MET versus
SU and
(2) log OR of experiencing a hypoglycaemic event during the
24 weeks for 0/1 OAD versus 2 OADs, as well as for MET
versus MET + SU, SU versus MET + SU and MET versus
SU.
For qualiﬁed studies, the effect size (log OR) was calculated
together with the standard error. Heterogeneity of effect sizes
was tested across trials with the Cochran Q test with I2
index [15]. A ﬁxed-effects meta-analysis model was used, with
the pooled effect for each grouping of trials weighted by the
estimated inverse of the variance (1/s.e.2). Random-effects
models also were used to estimate the pooled effect.
Results
Clinical Characteristics and Patient Demographics
Of 3801 patients, a total of 2171 in the 11 selected studies
were treated with insulin glargine and therefore examined for
PubMed search for ‘insulin 
glargine’ and ‘type 2 diabetes’
Date: Prior to 06/18/2010
N=972
Clinical trials identified in the 
sanofi-aventis database that met 
criteria for meta-analysis
N=5
-5 duplicates
n=977 titles screened for inclusion
n=119 abstracts screened
Other potential studies/
abstracts identified during 
abstract/article screening
N=5
Not randomized comparative trials; 
not in T2DM, not available in English, 
glycaemic control not an outcome; or 
included prandial insulin along with 
insulin glargine, n=858
n=19 full text articles reviewed 
for inclusion
Patients were not insulin naive; did 
not report % reaching HbA1c goal 
≤7.0% by OAD number and type, 
n=100
Did not report % reaching HbA1c goal 
≤7.0% by OAD number and type; did 
not follow treat-to-target insulin 
titration regimen, n=14
n=5 studies included in 
the meta-analysis
Figure 1. Flow of information through the systematic review.
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Table 2. Demographics and baseline characteristics by baseline OAD use in the pooled study and meta-analysis.
Baseline number of OADs Type of OAD
Characteristic∗ Overall 0/1 OAD 2 OADs MET SU MET + SU
Pooled study†
N 2154 1020 1134 185 792 1084
Age (years) 58.6 (10.1) 59.5 (10.6) 57.9 (9.5) 52.5 (9.9)‡ 61.2 (10.1)‡ 57.9 (9.5)‡
Sex (male; %) 55.6 56.0 55.3 51.9 56.4 54.9
Race (White; %) 88.3 90.7 85.8 71.9 95.6 86.1
Region (USA; %) 31.3 21.2 40.4 58.9 12.8 38.8
History of diabetes (years) 8.9 (6.2) 8.4 (6.0) 9.3 (6.4)§ 6.0 (4.1)‡ 9.1 (6.2)‡ 9.3 (6.4)‡
Baseline HbA1c (%) 8.77 (1.05) 8.87 (1.07) 8.68 (1.02) 9.08 (1.28) 8.84 (1.02) 8.67 (1.03)
Baseline FPG (mg/dl) 198.8 (52.3) 201.6 (51.6) 196.2 (52.7) 214.2 (60.2) 199.3 (49.4) 195.8 (52.9)
Baseline body weight (kg) 88.5 (17.7) 86.2 (17.4) 90.6 (17.7) 95.4 (19.8) 84.0 (16.3) 90.3 (17.5)
Meta-analysis 
N 928 271 657 97 135 609
Age (years) 57.1 (9.5) 56.8 (9.7) 57.3 (9.4) 53.8 (9.2) 58.8 (9.4) 57.2 (9.3)
Sex (male; %) 58.6 62.4 57.1 57.7 63.0 56.3
Race (White; %) 88.2 88.6 88.1 90.0 88.9 88.5
Region (USA; %) 32.2 21.0 36.8 21.6 25.2 34.0
History of diabetes (years) 8.3 (5.74) 6.6 (4.5) 9.0 (6.0) 5.8 (3.5) 7.5 (4.7) 9.1 (6.1)
Baseline HbA1c (%) 8.69 (1.04) 8.70 (1.11) 8.68 (1.00) 8.72 (1.20) 8.71 (1.08) 8.67 (1.01)
Baseline FPG (mg/dl) 199.7 (51.1) 195.4 (48.9) 201.5 (51.9) 198.2 (54.6) 194.7 (46.9) 201.3 (52.3)
Baseline body weight (kg) 90.8 (17.9) 89.9 (17.4) 91.2 (18.1) 94.9 (18.9) 88.0 (16.4) 90.7 (17.7)
FPG, fasting plasma glucose; MET, metformin; OAD, oral antidiabetic drug; SU, sulfonylurea.
∗Data are mean (s.d.) unless otherwise speciﬁed.
†n = 39 were not on any OAD; n = 71 were on ‘other’.
‡p < 0.05 for class comparison using an analysis of variance model with study and baseline OAD class as factors.
§p < 0.05 versus 0/1 OAD group.
 n = 36 were not on any OAD; n = 51 were on ‘other’.
inclusion in the pooled analysis. Before adding basal insulin,
approximately 1.8% of patients were taking no OAD, 45.2%
took 1 OAD and 52.2% took 2 OADs. Because only a very
small sample ofpatients [17 (0.8%)] were taking three ormore
OADs at baseline, these 17 were excluded from the analysis.
Nearly, half (49.9%) of all patients were taking MET + SU
combination therapy before basal insulin treatment; 36.5% of
patients took an SU only and 8.5% took a MET only. Partic-
ipants not taking MET or SU were not included in OAD class
analysis.
The demographics and baseline characteristics of the 2154
patients included in the ﬁnal pooled analysis are shown in
Table 2. Overall, the mean age of these patients was 58.6 years;
55.6% of patients were males, 88.3% were White and the
mean number of years from diabetes diagnosis to screening
was 8.9 years. The demographics and baseline characteristics
for patients taking 0/1 OAD and 2 OADs at baseline were
generallysimilar,although,asmightbeexpected,thoseinthe2
OADgroup hadalongerdurationofdiabetes (9.3vs.8.4 years,
p < 0.0001). Demographics and baseline characteristics for
patientstakingMETonly,SUonlyorbothatbaselinewerealso
generallysimilar,althoughthegroupsdifferedinage anddura-
tion of diabetes; patients taking MET alone were the youngest
and had the shortest disease duration.
Glycaemic Outcomes
For the primary outcome of interest, percentage of patients
reaching HbA1c ≤ 7.0% at week 24 after the addition of
basal insulin, results were similar between the 0/1 OAD
group and the 2 OAD group (54.7% vs. 56.7%, respectively,
p = 0.0541). However, more patients in the MET-only group
(68.1%)achievedHbA1c≤7.0%thanintheothergroups(50.4
and 56.4% for SU only and combination groups, respectively;
p = 0.0006forcomparisonamongallthreegroups,p = 0.0001
for MET vs. groups taking SUs). In addition, although there
was no difference in mean endpoint HbA1c between groups,
patients taking 0/1 OAD at baseline showed a signiﬁcantly
greater decrease in HbA1c from baseline to week 24 compared
with the 2 OAD group (p = 0.0198; ﬁgure 2). Patients in the
MET-only group experienced the largest mean improvement
in HbA1c from baseline (−2.0% vs. −1.7% in each of the
other two groups; p = 0.0006 for comparison among all three
groups, p = 0.0001 for MET vs. groups taking SUs).
Weight Change
Weight gain from baseline to week 24 was not signiﬁcantly
different, based on either the number or type of OAD therapy
at baseline (ﬁgure 3). However, the MET-only group had the
numerically lowest weight gain over 24 weeks (1.6 vs. 2.3 kg
in the SU-only group and 2.0 kg in the combination group,
p = 0.1830) after basal insulin initiation.
Insulin Dose
The stable weight-based insulin doses for patients on 0/1 OAD
and on 2 OADs were similar (0.45 vs. 0.43 U/kg); however,
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Figure 2. Change in HbA1c from baseline to week 24 by number and type of OAD at baseline (0/1 or 2; MET only, SU only, or both MET and SU).
p Values were calculated from an analysis of variance model with study and baseline OAD class as factors and baseline HbA1c as a covariate. MET,
metformin; OAD, oral antidiabetic drug; SU, sulfonylurea. *Least squares mean.
Figure 3. Change in body weight from baseline to week 24 by number and type of OAD at baseline (0/1 or 2; MET only, SU only, or both MET and SU).
p Values were calculated from an analysis of variance model with study and baseline OAD use as factors and baseline body weight as a covariate. MET,
metformin; OAD, oral antidiabetic drug; SU, sulfonylurea. *Least squares mean.
the mean insulin dose per kilogram in patients on MET only
was higher than that for patients on SU only or on SU + MET
combination therapy (0.54 vs. 0.43 vs. 0.43 U/kg, respectively).
As would be expected, insulin dose was positively correlated
with weight gain overall (Pearson r2 = 0.3167, p < 0.0001).
In the MET-only group, however, weight gain was statistically
similarandnumericallylowerthanintheothergroups,despite
the higher insulin dose.
Hypoglycaemia
As shown in Table 3, symptomatic, conﬁrmed symptomatic
with glucose <50 mg/dl and severe hypoglycaemia incidence
and rates were low overall. Patients in the 0/1 OAD group
had lower incidence and rates of symptomatic and conﬁrmed
(blood glucose <50 mg/dl) hypoglycaemia versus those taking
2 OADs, and those taking MET alone had lower incidence and
rates than those taking SU alone or in combination, with the
highest incidence in the MET + SU combination group. The
incidence of severe symptomatic hypoglycaemia followed the
same overall pattern, but did not reach statistical signiﬁcance.
Meta-analysis
As described in the section Methods, 5 of the 11 sanoﬁ-
aventis trials from the pooled analysis met the criteria for
inclusion in a meta-analysis, and no additional eligible studies
were found based on a systematic literature review (ﬁgure 1
and Table 1). The studies included in this analysis included
928 participants who were administered insulin glargine in
addition to 0/1 OAD (n = 271) or 2 OADs (n = 657); and
with MET only (n = 97), SU only (n = 135), or MET + SU
(n = 609). Baseline demographics and clinical characteristics
for this analysis population are shown in Table 2.
The results for the log OR of achieving glycaemic control
(HbA1c ≤7.0%) at 24 weeks with each regimen are shown in
ﬁgure 4. For each of the comparisons, the ﬁxed- and random-
effects models agreed, therefore, results from the ﬁxed-effects
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Table 3. Incidence and event rate of symptomatic, conﬁrmed symp-
tomatic with blood glucose <50 mg/dl and severe hypoglycaemia during
24 weeks.
Baseline OAD
number/class
Incidence,
n/N (%) p∗
Event rate per
subject-year,
least squares
mean (s.e.) p∗
Symptomatic hypoglycaemia
0/1 OAD 424/1020 (41.6) 0.0007 4.05 (0.71) 0.0009
2 OADs 713/1134 (62.9) 7.18 (0.43)
MET only 51/185 (27.6) <0.0001 1.81 (1.06) <0.0001
SU only 352/792 (44.4) 4.88 (0.90)
MET + SU 687/1084 (63.4) 7.30 (0.43)
Conﬁrmed symptomatic hypoglycaemia with blood glucose <50 mg/dl†
0/1 OAD 175/1013 (17.3) 0.0122 0.99 (0.22) 0.0643
2 OADs 375/1080 (34.7) 1.53 (0.13)
MET only 16/178 (9.0) 0.0006 0.67 (0.34) 0.0576
SU only 149/792 (18.8) 1.05 (0.27)
MET + SU 365/1030 (35.4) 1.56 (0.14)
Severe symptomatic hypoglycaemia†
0/1 OAD 12/1013 (1.2) 0.6444 0.01 (0.05) 0.4416
2 OADs 14/1080 (1.3) 0.06 (0.03)
MET only 2/178 (1.1) 0.6329 0.00 (0.07) 0.7231
SU only 10/792 (1.3) 0.02 (0.06)
MET + SU 14/1030 (1.4) 0.06 (0.03)
Event rate per subject-year = 365.25 × number of events/exposure(days).
MET, metformin; OAD, oral antidiabetic drug; s.e., standard error; SU,
sulfonylurea.
∗p Values for categorical variables were from Cochran–Mantel–Haenszel
statistics,whichtestgeneralassociationbetweenhypoglycaemiaeventsand
baseline OAD status. p Values for continuous variables were from analysis
of variance models, including study and baseline OAD status as factors.
†Study 6001 was excluded because no detailed information of
hypoglycaemia was collected.
model are presented. In addition, all comparisons met the
assumption for homogeneity with the Cochran Q,p> 0.05;
I2 = 0 except where noted. The log OR of reaching HbA1c
target slightly, but not signiﬁcantly, favoured the addition
of basal insulin to baseline therapy with 0/1 OAD versus
2 OADs [OR (95% conﬁdence interval): 0.261 (−0.057 to
0.580), p = 0.108; ﬁgure 4A], Cochran Q = 2.620, p = 0.623.
When analysed by the type of OAD, the estimated OR of
achieving HbA1c target was signiﬁcantly greater for the addi-
tion of basal insulin to baseline MET monotherapy versus
MET + SU combination [0.738 (0.218 to 1.258), p = 0.005]
or SU monotherapy [1.016 (0.377 to 1.656), p = 0.002]. There
was no signiﬁcant difference between baseline SU monother-
apy and MET + SU combination therapy (ﬁgure 4B–D),
Cochran Q,p> 0.40 for all and I2 = 0.956 for MET versus
MET + SU.
Resultsfromthemeta-analysisforfrequencyofsymptomatic
hypoglycaemia are shown in ﬁgure 5. Adding basal insulin to
0/1 OAD was associated with a signiﬁcantly lower risk of
hypoglycaemia versus adding basal insulin to 2 OADs [−0.546
(−0.860to−0.232),p = 0.001;CochranQ = 5.660,p = 0.226
and I2 = 29.332, ﬁgure 5A). Likewise, risk of hypoglycaemia
was lower with baseline MET monotherapy versus MET + SU
combinationtherapy[−1.260(−1.751to−0.768),p < 0.001]
or SU monotherapy [−0.987 (−1.594 to −0.380), p = 0.001].
There was no signiﬁcant difference between baseline therapy
with SU alone and MET + SU combination therapy (Cochran
Q,p> 0.10 for all and I2 = 49.72 for SU vs. MET + SU,
ﬁgure 5B–D).
Discussion
In this large, pooled analysis of prospective, randomized, con-
trolled clinical trials in patients with type 2 diabetes, more
than half of the patients previously uncontrolled on 0, 1 or
2 OADs with baseline HbA1c of 8.7–9.1% achieved a target
HbA1c ≤7.0% after 24 weeks of treatment with the addition of
basalinsulin,whilecontinuingtheoralagent(s).Patientstaking
METalonebeforetheinitiationofbasalinsulinhadthegreatest
HbA1creductionsandthelargestproportionofpatientsachiev-
ingglycaemicgoalatweek24comparedwithpatientstakingan
SU alone or in combination with MET. Hypoglycaemia rates
were low overall. Patients on MET only at baseline also had
the lowest rate of symptomatic and severe hypoglycaemia and
the lowest weight gain after 24 weeks of treatment with insulin
glargineinspiteofahigherinsulindoseonaverage.Theresults
from this pooled analysis were supported by a meta-analysis of
ﬁve eligible studies from the trial cohort in which the OR of
achieving glycaemic goals at week 24 was signiﬁcantly higher
andriskofsymptomatichypoglycaemiawassigniﬁcantlylower
for patients taking MET alone before initiation of basal insulin
compared with those taking an SU alone or in combination
with MET.
These data illustrate that adding basal insulin in patients
whose hyperglycaemia remained uncontrolled on 0/1 OAD
(and particularly to MET monotherapy) resulted in greater
HbA1c reductions and lower rates of hypoglycaemia after 24
weeks than adding basal insulin to 2 OADs. These ﬁndings
provide evidence-based clinical trial support for the success of
the tier 1 consensus strategy from the ADA/EASD [1], recom-
mending the addition of basal insulin (or SU therapy) to MET
monotherapy plus lifestyle intervention at step 2 (i.e. if MET
plus lifestyle intervention alone is unable to achieve glycaemic
control).
Moreover, these preliminary observations suggest the value
ofaddingbasalinsulintoMETmonotherapyearlyintheclinical
management of type 2 diabetes as a viable option for achieving
glycaemic control, because patients on 0/1 OAD in the trials
analysed here were at an earlier stage of their type 2 diabetes.
These ﬁndings have notable clinical implications, given that
a common strategy in real-world clinical practice is to delay
insulin initiation in patients with type 2 diabetes for as long
as possible. Although patient concerns and other barriers to
the implementation of insulin therapy are important to con-
sider, clinical evidence continues to accumulate highlighting
theurgentneedtoovercomethesebarrierstomaximizepatient
beneﬁt by initiating insulin therapy earlier in the course of the
disease.Thisiscertainlypossibleintoday’streatmentlandscape,
with the availability of long-acting basal insulin formulations
that can be administered once daily and titrated using sim-
ple algorithms. In addition, insulin pen delivery devices make
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A. 
B. 
C. 
D. 
Study name Log odds ratio and 95% CI
3502 0.324 0.294 -0.253 0.901 0.271
4002 0.000 0.280 -0.549 0.549 1.000
4040 0.242 0.334 -0.412 0.896 0.469
4041 0.814 0.548 -0.261 1.889 0.138
6001 0.990 0.880 -0.734 2.715 0.260
0.261 0.162 -0.057 0.580 0.108
-2.50 -1.25 0.00 1.25 2.50
Favours 2 OADs Favours 0/1 OAD
Meta-Analysis of Log Odds Ratio of Week 24 HbA1c no greater than 7% vs. OAD use (0/1 vs. 2)
Odds Ratio = odds of Week 24 HbA1c ≤ ≤ 7% for 0/1 OAD / odds of Week 24 HbA1c ≤ ≤ 7% for 2 OAD.
Study name Log odds ratio and 95% CI
3502 0.786 0.416 -0.030 1.601 0.059
4002 0.237 0.432 -0.609 1.083 0.583
4040 1.655 1.069 -0.440 3.750 0.122
4041 2.190 1.065 0.104 4.277 0.040
6001 0.990 0.880 -0.734 2.715 0.260
0.738 0.265 0.218 1.258 0.005
-2.50 -1.25 0.00 1.25 2.50
Favours MET/SU Favours MET
Meta-Analysis of Log Odds Ratio of Week 24 HbA1c ≤  ≤ 7% vs. OAD Use (MET vs. MET/SU)
Odds Ratio = odds of Week 24 HbA1c ≤ ≤ 7% for MET / odds of Week 24 HbA1c ≤ ≤ 7% for MET/SU.
Study name Log odds ratio and 95% CI
3502 1.322 0.482 0.377 2.266 0.006
4002 0.364 0.529 -0.673 1.401 0.491
4040 1.596 1.096 -0.553 3.745 0.145
4041 1.792 1.208 -0.575 4.159 0.138
1.016 0.326 0.377 1.656 0.002
-4.00 -2.00 0.00 2.00 4.00
Favours SU only Favours MET only
Meta-Analysis of Log Odds Ratio of Week 24 HbA1c   ≤ ≤ 7% vs. OAD Use (MET vs. SU)
Odds Ratio = odds of Week 24 HbA1c ≤ ≤ 7.0% for MET alone / odds of Week 24 HbA1c ≤ ≤ 7.0% for SU only.
Study name Log odds ratio and 95% CI
3502 -0.536 0.396 -1.312 0.240 0.176
4002 -0.127 0.356 -0.824 0.570 0.721
4040 0.058 0.350 -0.628 0.745 0.867
4041 0.398 0.652 -0.879 1.676 0.541
-0.121 0.201 -0.515 0.272 0.545
-2.50 -1.25 0.00 1.25 2.50
Favours MET/SU Favours SU
Meta-Analysis of Log Odds Ratio of Week 24 HbA1c ≤  ≤ 7% vs. OAD Use (SU vs. MET/SU)
Odds Ratio = odds of Week 24 HbA1c ≤ ≤ 7% for SU / odds of Week 24 HbA1c ≤ ≤ 7% for MET/SU.
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Figure 4. Meta-analysis results of log odds ratios for achieving HbA1c ≤7.0% at week 24 with baseline OAD use of (A) 0/1 versus 2 OADs, (B) MET only
versus MET + SU, (C) MET monotherapy versus SU monotherapy and (D) SU monotherapy versus MET + SU. Because all patients in study 6001 were
taking either MET monotherapy or combination therapy with MET + SU, this study was not included in comparisons with SU monotherapy (panels C
a n dD ) .C I ,c o n ﬁ d e n c ei n t e r v a l ;M E T ,m e t f o r m i n ;O A D ,o r a la n t i d i a b e t i cd r u g ;S U ,s u l f o n y l u r e a .
injections easier and more convenient for patients. Keys to
implementingthisstrategyincludeincreasingphysicianaware-
ness of the importance of earlier insulin initiation and patient
education regarding the need for improved glycaemic control
if targets are not being met.
Strengths of this analysis are its large size (including data
from more than 2000 patients treated with basal insulin in 11
clinicaltrialsevaluatedinthepooledanalysis),widegeographic
variationand reliance on datafromprospective, controlledtri-
als. In addition, although the sample sizes for each of the
OAD treatment groups differed substantially, these differences
were eliminated when evaluating effects with a meta-analysis.
Speciﬁcally, the number of patients on MET monotherapy
prior to randomization was much smaller than those in the
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3502 -0.447 0.290 -1.016 0.122 0.123
4002 -1.009 0.300 -1.597 -0.422 0.001
4040 -0.045 0.313 -0.658 0.567 0.884
4041 -0.896 0.486 -1.848 0.056 0.065
6001 -0.323 0.815 -1.921 1.275 0.692
-0.546 0.160 -0.860 -0.232 0.001
-2.00 -1.00 0.00 1.00 2.00
2 OADs Higher 0/1 OAD Higher
Meta-Analysis of Log Odds Ratio of Symptomatic Hypoglycaemia vs. OAD Use (0/1 vs. 2 OADs)
Odds Ratio = odds of symptomatic hypoglycaemia for 0/1 OAD / odds of symptomatic hypoglycaemia for 2 OADs.
Study name Log odds ratio and 95% CI
3502 -1.198 0.409 -2.000 -0.397 0.003
4002 -1.428 0.434 -2.279 -0.577 0.001
4040 -1.534 0.809 -3.119 0.052 0.058
4041 -1.558 0.800 -3.126 0.010 0.051
6001 -0.323 0.815 -1.921 1.275 0.692
-1.260 0.251 -1.751 -0.768 0.000
-3.50 -1.75 0.00 1.75 3.50
MET/SU Higher MET Higher
Meta-Analysis of Log Odds Ratio of Symptomatic Hypoglycaemia vs. OAD Use (MET vs. MET/SU)
Odds Ratio = odds of symptomatic hypoglycaemia for MET alone / odds of symptomatic hypoglycaemia for MET/SU combo.
Study name Log odds ratio and 95% CI
3502 -1.201 0.475 -2.132 -0.270 0.011
4002 -0.424 0.530 -1.463 0.615 0.424
4040 -1.723 0.843 -3.375 -0.070 0.041
4041 -1.012 0.983 -2.938 0.915 0.303
-0.987 0.310 -1.594 -0.380 0.001
-4.00 -2.00 0.00 2.00 4.00
SU higher rate MET higher rate
Meta-Analysis of Log Odds Ratio of Symptomatic Hypoglycaemia vs. OAD Use (MET vs. SU)
Odds Ratio = odds of subjects with symptomatic hypoglycaemia for MET alone / odds of symptomatic hypoglycaemia for SU alone.
Study name Log odds ratio and 95% CI
3502 0.003 0.397 -0.775 0.780 0.995
4002 -1.004 0.393 -1.774 -0.234 0.011
4040 0.189 0.340 -0.476 0.855 0.577
4041 -0.547 0.651 -1.823 0.730 0.401
-0.257 0.205 -0.658 0.144 0.209
-2.00 -1.00 0.00 1.00 2.00
MET/SU Higher SU Higher
Meta-Analysis of Log Odds Ratio of Symptomatic Hypoglycaemia vs. OAD Use (SU vs. MET/SU)
Odds Ratio = odds of symptomatic hypoglycaemia for SU alone / odds of symptomatic hypoglycaemia for MET/SU combo.
Figure 5. Meta-analysis results of log odds ratios for experiencing symptomatic hypoglycaemia with baseline OAD use of (A) 0/1 versus 2 OADs,
(B) MET monotherapy versus MET + SU, (C) MET monotherapy versus SU monotherapy and (D) SU monotherapy versus MET + SU. Because all
patients in study 6001 were taking either MET monotherapy or combination therapy with MET + SU, this study was not included in comparisons with
SU monotherapy (panels C and D). CI, conﬁdence interval; MET, metformin; OAD, oral antidiabetic drug; SU, sulfonylurea.
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other two groups, and the results from the meta-analysis
were consistent with the pooled analysis in that adding basal
insulin to MET monotherapy provided beneﬁcial glycaemic
control.
Onemajorlimitationofthisanalysiswasthatonlystudies of
insulin glargine were evaluated in both the pooled and meta-
analyses; thus, applicability to other basal insulin formulations
(e.g. NPH insulin and insulin detemir) is unknown. It should
also be noted that our analyses focus on the number and
type of OADs that were used at initiation of basal insulin
glargine. The OADs were to be maintained over 24 weeks
of treatment in all studies; however, we did not assess if
any changes did occur in OADs during the course of this
study. Therefore, these results provide important information
to be considered by clinicians speciﬁc to deciding when to
initiate insulin therapy in people failing OAD treatment.
The best approach for optimizing and maintaining glycaemic
control over time should be individualized for each patient.
Furthermore,thisstudyaddressesoutcomesfollowing24weeks
of treatment; the impact on longer term outcomes such as
clinical complications or death was not assessed. Another
limitation of this analysis is that although statistical pooling of
data in pooled- and meta-analyses increases statistical power
and may result in more precise estimates of therapeutic
effect, these are hypotheses generating analyses; additional
randomizedcontrolledclinicaltrialsareneededtodrawreliable
conclusions.
In conclusion, patients adding basal insulin glargine to
0/1 OAD at baseline, who are in earlier stages of type 2
diabetes, showed a greater reduction in HbA1c with lower
risk of hypoglycaemia than those failing 2 OADs at baseline.
In particular, adding insulin glargine to MET monotherapy
was well tolerated and resulted in a signiﬁcant proportion of
patients achieving the glycaemic goal of HbA1c ≤7.0% with a
low risk of hypoglycaemia and weight gain, in spite of a higher
insulin dose used on average. These ﬁndings suggest that some
patients may beneﬁt from the initiation of basal insulin earlier
in the management of type 2 diabetes than often occurs in
this clinical practice, which further corroborates the guidance
outlined for the clinical management of type 2 diabetes by the
ADA and EASD.
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